MYH9 and cancer: We verified that TM4SF1 could activate the NOTCH signaling pathway by positively regulating MYH9, which ultimately promoted the cancer stemness in HCC and enhanced the drug resistance of HCC cells to Lenvatinib (Additional file 3: Fig. S2).